Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Although tumor heterogeneity is widely accepted, the existence of cancer stem cells (CSCs) and their proposed role in tumor maintenance has always been challenged and remains a matter of debate. Recently, a path‐breaking chapter was added to this saga when three independent groups reported the in vivo existence of CSCs in brain, skin and intestinal tumors using lineage‐tracing and thus strengthens the CSC concept; even though certain fundamental caveats are always associated with lineage‐tracing approach. In principle, the CSC hypothesis proposes that similar to normal stem cells, CSCs maintain self renewal and multilineage differentiation property and are found at the central echelon of cellular hierarchy present within tumors. However, these cells differ from their normal counterpart by maintaining their malignant potential, alteration of genomic integrity, epigenetic identity and the expression of specific surface protein profiles. As CSCs are highly resistant to chemotherapeutics, they are thought to be a crucial factor involved in tumor relapse and superficially appear as the ultimate therapeutic target. However, even that is not the end; further complication is attributed by reports of bidirectional regeneration mechanism for CSCs, one from their self‐renewal capability and another from the recently proposed concept of dynamic equilibrium between CSCs and non‐CSCs via their interconversion. This phenomenon has currently added a new layer of complexity in understanding the biology of tumor heterogeneity. In‐spite of its associated controversies, this area has rapidly emerged as the center of attention for researchers and clinicians, because of the conceptual framework it provides towards devising new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“In late Nineties, Dick group in their pioneering studies, first documented and characterized the existence of CSCs in hematopoietic malignancies.(18) Later, the CSC concept has been extensively expanded to cover most of the solid tumors.”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“Importantly, CSC rich tumors are associated with aggressive disease, drug resistance and poor prognosis.(10) CSC model advocates the presence of tumorigenic stem-like cells in heterogeneous tumors, which differentiate into less-tumorigenic cancer cells to create a cellular hierarchy.”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 1×
“Heterogeneity among cancer cells arises within the same tumor as a consequence of intrinsic, such as genetic(4) and epigenetic changes(5) as well as extrinsic factors like varied microenvironment at different spatial locations.(6) Tumor cell heterogeneity may result from either clonal evolution driven by genetic insta…”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
The Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019
Distinct stem cells contribute to mammary gland development and maintenance
Van Keymeulen, A., Rocha, A. S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., & Blanpain, C. (2011) · Nature · doi:10.1038/nature10573 · Cited by 854 · cited 1×
“For example, lineage tracing in mammary and epidermal cell transplantation studies have shown that the labelled cells acquire multipotent phenotype though this is not observed in the event of lineage tracing in undamaged tissues.(39) High coverage sequencing of human tumors as well as live imaging of human tumors is e…”
BackgroundHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813 · cited 1×
“Unlike HIF1a, HIF2a acts as a transcriptional activator of stemness specific genes OCT4, SOX2, CD44, KLF-4, MYC, etc.(93) Hence, it is noteworthy that these newly discovered signaling pathways act in synergistic manner with an overall goal of inducing stemness and further elucidation of their complex crosstalk will he…”
BackgroundSingle-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., Li, F., Tsang, S., Wu, K., Wu, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.025 · Cited by 667
Humke, E. W., Dorn, K. V., Milenkovic, L., Scott, M. P., & Rohatgi, R. (2010) · Genes & Development · doi:10.1101/gad.1902910 · Cited by 444 · cited 1×
“The transcriptional program orchestrated by Hedgehog signaling depends on the Gli family of transcription factors.(81) Although Gli proteins can be converted to either transcriptional activators or truncated transcriptional repressors, Hedgehog-Gli interaction ultimately enhances self renewal properties and CSC plasti…”
BackgroundHirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440
Iliopoulos, D., Lindahl-Allen, M., Polytarchou, C., Hirsch, H. A., Tsichlis, P. N., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.013 · Cited by 399 · cited 9×
“This effect of PRC1 in postponing the commitment of stem cells has been found to be mediated by its BMI1 (B cell specific Moloney murine leukemia virus integration site 1) component via interacting with Ring1b.67 Furthermore, BMI1 and EZH2 are overexpressed in CSCs and found to be necessary for tumor initiation of var…”
BackgroundInfluentialChan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391 · cited 1×
“Recently, pharmacological inhibitors of S phase kinase associated protein 2 (SKP2) have been demonstrated to effectively inhibit CSCs and considered for their therapeutic potential.(102,103) However, as SKP2 is also involved in general metabolism, clinical efficacy and toxicological concerns of its inhibitors need to…”
Background
Cited by
HIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Numerous factors are responsible for intratumoral heterogeneity, the most important is genomic variability caused by mutagen exposure like UV radiations, chemicals, chemotherapy, or dysregulation of signaling processes that maintain DNA repair, and redox balance of cells [42, 50–53].”
BackgroundAutophagy and disease: unanswered questions
Yang, Y., & Klionsky, D. J. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0480-9 · Cited by 369
Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis
Wang, X., Sun, W., Shen, W., Xia, M., Chen, C., Xiang, D., Ning, B., Cui, X., Li, H., Li, X., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.019 · Cited by 290
The Roles of ROS in Cancer Heterogeneity and Therapy
de Sá Junior, P. L., Câmara, D. A. D., Porcacchia, A. S., Fonseca, P. M. M., Jorge, S. D., Araldi, R. P., & Ferreira, A. K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2467940 · Cited by 287
Metadata
- Authors
- Singh, A. K., Arya, R. K., Maheshwari, S., Singh, A., Meena, S., Pandey, P., Dormond, O., & Datta, D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-03-04
- Volume
- 136
- Issue
- 9
- Pages
- 1991-2000
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2126973041
- Cited by
- 139
- References
- 19
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.